Trial Profile

A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene galvacirepvec; Rilimogene glafolivec
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

02 Nov 2022 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results(n=24) assessing Immune changes after enzalutamide is added to androgen-deprivation therapy in first-line metastatic castration-resistant prostate cancer presented at the 47th European Society for Medical Oncology Congress
22 Jun 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com